Orphan Drugs and Rare Diseases Global Congress 2018 Europe

3.2 from 11 votes
Date: 07 - 09 March, 2018
Location: London, England

In the United States, a rare disease is defined as a condition affecting fewer than 200,000 people. In EU countries, any disease affecting fewer than 1 in 2,000 people is considered rare. That number may seem small, but it translates into approximately 246 000 people throughout the EU's 28 member countries. Most patients suffer from even rarer diseases affecting 1 person in 100,000 or more.

There are more than 7,000 rare diseases identified, however, only a fraction of them have approve treatment available. "Orphan drugs" are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions. Currently, the regulatory climate is favourable with both FDA and European Medicines Agency, as they offer incentives, tax credits, user waivers and marketing exclusivity. As a result, the number of therapies approved for rare diseases for the past two decades has grown exponentially.

Paradigm Global Events is again proud to present its bi-annual Orphan Drugs & Rare Diseases Global Congress 2018 Europe. The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing and more. We look forward to having you be part of the event!

The two-day Congress will provide an interactive, cutting edge and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.

Gain Latest Insights On

Key Economic Drivers in the Orphan Market: What is Driving the Industry and the Role of Governments?
Growing the Market: The Roles of Big Pharmas, Biotechs and Start-Ups
Emerging Markets: Challenges and Benefits in Investing in Emerging Markets
Europe's Regulatory Landscape: What Works and What Doesn't?
Medical Devices in the Orphan Realm: Barriers and Opportunities for Medical Devices in Small Populations
Strategic Partnerships: What Strategies are available to Ensure Partnership Success
Pricing Strategy: How to Price Correctly?
Clinical Trials: From Early Drug Development to Patient Recruitment and More

Who will you meet

Presidents, Heads/Chiefs, Directors, VPs and Managers of Research and Development, Regenerative Medicine, External R&D Innovation, Immunology, Clinical Scientist, Cell & Gene, Therapy, Translational Science, Molecular Geneticist, Program Management, Patient Advocacy and Public Affairs, Medical Affairs, Regulatory Affairs, Clinical Field Specialist, Sales and Marketing, Outcomes & Evidence, Commercial Development, Product Specialist, Global Strategic Services, Business Planning and Operations

Featuring Key Industry Experts

Ségolène Aymé, Emeritus Director of Research, INSERM, Founder, Orphanet
Michael Zaiac, Head of Medical Affairs Haematology/Oncology, EMEA, Celgene
Didier Caizergues, Head of Regulatory Affairs Department, GENETHON
Otto Schwarz, former COO, Actelion Pharmaceutical Ltd.
Eduardo Garcia, Senior Vice President and General Counsel, World Rare Disorder Foundation
Christian Girard, Chief Editor, Orphan Drugs Industry Insider
Gilles Vassal, President, European Society for Paediatric Oncology
Jeff Davies, Head, Corporate Development, Acer Therapeutics Inc.
Ken Kengatharan, Chairman at Renexxion, Managing General Partner, Atheneos Capital
Jaswinder Khera, Managing Director Americas, WEP Clinical
Amandip Sidhu, EAP Director, WEP Clinical
Mike Page, Executive Director, Global Regulatory Affairs Portfolio Products, Alexion Pharmaceuticals
Robert Meadowcroft, Chief Executive, Muscular Dystrophy UK
Alastair Kent OBE, Ambassador, Genetic Alliance UK, Chair, Rare DiseaseUK
Dr Nicolas Sireau, Chair, AKU Society
Richard Thompson, CEO, Findacure
Rene Westhovens MD PhD, President Orphan Drug Colleges and Commission, INEMI-RIZIB
Josie Godfrey, Director, JG Zebra Consulting, Former Associate Director of HST, NICE*
Dr. David Gillen, Vice- President, International Medical Affairs, Vertex
Matthew Lumley, Rare Disease Medical Director, Pfizer UK
Martina Garau, Principal Economist, The Office of Health Economics
Raúl Insa, MD, PhD, MBA, Founder, President and CEO, SOM Biotech
Leone Atkinson, M.D. Ph.D, Executive Medical Director, Covance Rare Disease and Orphan Drugs
Fred Derosier, D.O.,Executive Director, Covance Rare Diseases and Orphan Drugs
Kay Parkinson, Chief Executive Officer, Cambridge Rare Diseases Network
Irina Cleemput, Senior Health Economist, Belgian Health Care Knowledge Centre (KCE)
Leslie Galloway, Chairman, EMIG
Francis Pang, VP of Global Market Access, Amicus
Thomas Cawston, Head of Healthcare Policy, Hanover
Sjef De Kimpe, PhD, MBA, CSO and SVP, R&D, Auxesia Orion
Dr Carlos R. Camozzi, Orphan Drugs Development and Rare Diseases Expert
Nic Bungay, Director of Campaigns, Care and Information
Senior Representative from NICE


3.2 from 11 votes